PMID- 30508272
OWN - NLM
STAT- MEDLINE
DCOM- 20200608
LR  - 20200608
IS  - 1522-726X (Electronic)
IS  - 1522-1946 (Linking)
VI  - 93
IP  - 6
DP  - 2019 May 1
TI  - Myocardial fibrosis predicts adverse outcome after MitraClip implantation.
PG  - 1146-1149
LID - 10.1002/ccd.27993 [doi]
AB  - BACKGROUND: High-risk patients with mitral regurgitation (MR) may be treated by a 
      percutaneous mitral valve repair with the MitraClip, but identification of 
      patients who may benefit remains difficult. We aimed to determine whether 
      myocardial fibrosis predicts outcome in MR patients undergoing MitraClip 
      implantation and is beneficial in clinical decision making. METHODS: 
      Preprocedural to the MitraClip implantation, myocardial fibrosis was analyzed 
      with cardiovascular magnetic resonance (CMR) through late gadolinium enhancement. 
      The CMR data were core-lab adjudicated measured before the MitraClip 
      implantation. Adverse outcome was defined as New York Heart Association (NYHA) 
      class III or IV after 1 month or death within 1 month after the MitraClip 
      implantation. RESULTS: In total, 23 patients underwent preprocedural CMR, mean 
      age 80 +/- 9 years, 45% male, 64% atrial fibrillation and 73% NYHA class III or IV 
      at baseline. Myocardial fibrosis was present in 55% of the patients with 
      degenerative MR and in 64% of the patients with functional MR. An adverse outcome 
      occurred in 69% of the patients with myocardial fibrosis and in 11% of the 
      patients without myocardial fibrosis (P = 0.01). CONCLUSIONS: Our 
      hypothesis-generating study showed that the presence of myocardial fibrosis 
      predicts adverse outcome in patients undergoing MitraClip implantation. After 
      confirmation with larger sample size, identification of myocardial fibrosis might 
      contribute to assess prognosis and to clinical decision making.
CI  - (c) 2018 Wiley Periodicals, Inc.
FAU - Velu, Juliette F
AU  - Velu JF
AUID- ORCID: 0000-0002-2534-0752
AD  - Department of Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, Heart 
      Center, University of Amsterdam, Amsterdam, The Netherlands.
FAU - Hirsch, Alexander
AU  - Hirsch A
AD  - Department of Cardiology and Radiology, Erasmus Medical Center, Rotterdam, The 
      Netherlands.
FAU - Boekholdt, S M
AU  - Boekholdt SM
AD  - Department of Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, Heart 
      Center, University of Amsterdam, Amsterdam, The Netherlands.
FAU - Koch, Karel T
AU  - Koch KT
AD  - Department of Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, Heart 
      Center, University of Amsterdam, Amsterdam, The Netherlands.
FAU - Marije Vis, M
AU  - Marije Vis M
AD  - Department of Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, Heart 
      Center, University of Amsterdam, Amsterdam, The Netherlands.
FAU - Nils Planken, R
AU  - Nils Planken R
AD  - Department of Radiology and Nuclear Medicine, Amsterdam UMC, University of 
      Amsterdam, Amsterdam, The Netherlands.
FAU - Piek, Jan J
AU  - Piek JJ
AD  - Department of Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, Heart 
      Center, University of Amsterdam, Amsterdam, The Netherlands.
FAU - Baan, Jan Jr
AU  - Baan J Jr
AD  - Department of Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, Heart 
      Center, University of Amsterdam, Amsterdam, The Netherlands.
FAU - Bouma, Berto J
AU  - Bouma BJ
AD  - Department of Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, Heart 
      Center, University of Amsterdam, Amsterdam, The Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20181203
PL  - United States
TA  - Catheter Cardiovasc Interv
JT  - Catheterization and cardiovascular interventions : official journal of the 
      Society for Cardiac Angiography & Interventions
JID - 100884139
SB  - IM
CIN - Catheter Cardiovasc Interv. 2019 May 1;93(6):1150-1151. PMID: 31025522
MH  - Aged
MH  - Aged, 80 and over
MH  - Clinical Decision-Making
MH  - Decision Support Techniques
MH  - Female
MH  - Fibrosis
MH  - *Heart Valve Prosthesis
MH  - Heart Valve Prosthesis Implantation/*adverse effects/*instrumentation/mortality
MH  - Humans
MH  - Magnetic Resonance Imaging, Cine
MH  - Male
MH  - Mitral Valve/diagnostic imaging/*surgery
MH  - Mitral Valve Insufficiency/diagnostic imaging/mortality/pathology/*surgery
MH  - Myocardium/*pathology
MH  - Prosthesis Design
MH  - Risk Assessment
MH  - Risk Factors
MH  - Time Factors
MH  - Treatment Outcome
OTO - NOTNLM
OT  - MitraClip
OT  - myocardial fibrosis
OT  - percutaneous mitral valve repair
EDAT- 2018/12/07 06:00
MHDA- 2020/06/09 06:00
CRDT- 2018/12/04 06:00
PHST- 2018/09/10 00:00 [received]
PHST- 2018/10/16 00:00 [revised]
PHST- 2018/11/04 00:00 [accepted]
PHST- 2018/12/07 06:00 [pubmed]
PHST- 2020/06/09 06:00 [medline]
PHST- 2018/12/04 06:00 [entrez]
AID - 10.1002/ccd.27993 [doi]
PST - ppublish
SO  - Catheter Cardiovasc Interv. 2019 May 1;93(6):1146-1149. doi: 10.1002/ccd.27993. 
      Epub 2018 Dec 3.